Abstract Purpose: To compare volumetric-modulated arc therapy (VMAT) with 3D-conformal radiation therapy (3D-CRT) mediastinal irradiation for stage I-II supra-diaphragmatic Hodgkin's Lymphoma (HL). Patients and methods: Eleven patients were planned for RT after 4-6 cycles of ABVD chemotherapy: conventional 3D-CRT (AP/PA) and VMAT plans were conformed to the same PTV. Objective was to choose the best PTV coverage plan with the least OAR dose. The 2 plans were compared for: PTV coverage, mean dose and V5,V20 lung , mean dose and V30 heart , V5, V10, V15 breast (female patients), and the integral body dose. Results: Both techniques achieved adequate PTV coverage. Mean lung and heart dose was consistently lower in VMAT plans. The lung V20 dose was acceptable for VMAT, but exceeded the tolerance threshold in 6 cases with 3DCRT plans. A mean difference of 15.9% for both lungs V20 favored VMAT plans; average MLD difference was 2.3 Gy less for VMAT plans. Similarly, lower maximum and mean heart doses with a 3.3 Gy dose reduction and a 9.4% difference in V30 favored VMAT plans. Mean V5 lung/female breast and integral dose were invariably higher in VMAT plans because of the low-dose spread. Conclusions: VMAT is a valuable technique for treatment of large mediastinal HL. VMAT spares the lung and heart compared to 3DCRT using ISRT in select HL cases. VMAT allows dose escalation for post-chemotherapy residual disease with minimal dose to OARs. VMAT low radiation dose (V5) to the normal tissues, and the increased integral dose should be considered.
Introduction
Radiation therapy (RT) is the most effective single modality for local control in Hodgkin's Lymphoma (HL), and is commonly used as a component of combined modality therapy (CMT) in many patients. Guidelines have been developed to address the use of RT in the modern era of CMT, moving from extended field (EF) to involved-field RT (IFRT), and more recently to involved-site RT (ISRT), using 3D-CRT planning and other advanced techniques such as intensity modulated RT (IMRT), Rapidarc (RA), and optimized volumetric modulated arc therapy (VMAT) for treatment delivery [1] [2] [3] . 3D-CRT generated AP/PA field plan, with field-in-field compensation for dose homogeneity still remains the standard techniques in many patients. There are situations where complex anatomy and tumor location make IMRT and VMAT superior to conventional 3D-CRT techniques [4, 5] .
In this study, the intention was to explore the use of VMAT in stage I-II patients with supra-diaphragmatic disease, particularly those presenting with large mediastinal disease volume, with or without neck/axillary involvement, where the OAR dose constraints cannot be met using the conventional 3D-CRT.
Patients and methods
The whole cohort included 11 patients with mediastinal HL with or without involvement of the neck/axilla. There were 4 females and 7 males. Three patients presented with mediastinal disease only, and 8 with mediastinal, neck and/or axillary involvement. Planning CT scan was acquired for the neck and chest in contiguous 3 mm thickness slices on a Philips large-bore CT simulator (Brilliance big bore V2.3.017184). Patients were scanned in the supine position with the head and shoulders immobilized in a thermoplastic shell. 4-D CT sets were acquired in free breathing, deep inspiration and expiration.
Contouring the target volumes (GTV, CTV, ITV and PTV) were done based on the pre-and post-chemotherapy PET-CT imaging according to the International Lymphoma Radiation Oncology Group (ILROG) recommendations and guidelines for involved-site irradiation (ISRT) [4] . Residual mediastinal mass were localized as the post-chemo GTV. CTV included the pre chemo GTV superior and inferior disease extension, and edited for masses that initially encroached laterally on the lungs, but regressed on chemotherapy. Internal target volume (ITV) was created on the free breathing CT, using the information acquired from expiration and deep inspiration CT scans, to account for respiratory movements. PTV was then created by 1 cm margin isotropic expansion of the ITV, except for the neck nodal area where a 0.5 cm margin was used for the CTV. The organs at risk were delineated (OARs: lungs, heart, thyroid, salivary glands and spinal cord).
Patients included in this study had pathologically proven HL stage IB-IIBX. All patients were treated using combined modality treatment; 4 and 7 patients were treated by 4 and 6 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) chemotherapy regimen respectively. Nine and two patients achieved complete (CR) and partial remission (PR) respectively evidenced by PET-CT scans. Thereafter all patients were treated by Involved Field RT (30.6 Gy/20 Fx/3.5 weeks for CR patients and 36 Gy/20 Fx/4 weeks for PR ones).
VMAT plans were optimized using a complete 360 degree arc or hemi-arcs or non-coplanar small arcs. The VMAT plans were inversely planned using Pinnacle. Conventional RT opposed AP/PA plans were generated using 3D-CRT, fashioned to the same PTV in different clinical scenarios cases. The primary objective was to identify for each case the technique which provides an adequate PTV coverage with the least dose to the OARs.
For all patients, the resulting plans were normalized to a prescribed dose of 30.6 Gy in 1.8 Gy fractions with 95% of the dose to 100% of the PTV. Two patients had post-chemotherapy metabolic residual disease and received additional 6 Gy boost to the site of residual disease. Dose-volume histograms (DVH) were used for evaluation and estimation of OAR doses. Comparison was made between 3D-CRT and VMAT for PTV coverage, V5, V20 and mean lung dose, as well as V30 heart, mean and maximum doses, and the integral dose. In addition V5, 10, 15 and mean dose to the breasts were estimated for female patients. Dose constraints to the heart, lungs and other OARs were defined according to the QUANTEC organ-specific dose/volume/outcome data, based on the QUANTEC reviews guidelines [6] .
Results
Dose-volume parameters and mean dose value statistics for 3D-CRT and VMAT plans for the complete cohort of 11 patients treated to the prescribed dose are displayed in Table 1 .
The dose prescription was normalized to 30.6 Gy in all cases except for two patients who had pot-chemotherapy residual active disease, where the dose was prescribed to 30.6 Gy with an additional 5.4 Gy boost to area of residual disease (total dose 36 Gy).
Homogeneous dose coverage of PTV was achieved in both 3D-CRT and VMAT plans, with 100% of PTV covered by at least 95% of the dose (Fig. 1) . Only in one case who presented with bulky mediastinal disease, sub-pectoral and axillary nodes, PTV coverage lower than the 95% dose normally achieved was accepted because of the PTV-lungs overlap, and the 95% coverage plan would have exceeded the lung metrics.
The mean dose for lungs and heart was lower in VMAT plans ( Table 1) . The V20 and mean dose to lungs were within the acceptable range for VMAT, but exceeded the normal acceptable levels for the 3D-CRT plans in 6 cases with bulky mediastinal disease and/or sub-pectoral/axillary involvement. For the whole cohort of patients, a mean difference of 15.9% was noticed for V20 of both lungs in favor of VMAT. The mean dose to both lungs was 2.3 Gy less for VMAT plans. Similarly, maximum and mean doses to the heart were much lower with VMAT; there was an average reduction of 3.3 Gy of the mean heart dose and a 9.4% difference in V30 in favor of VMAT plans. An illustrative DVH comparison for a female patient is shown in Fig. 2 . The mean V5 breast and lung for the whole cohort of patients was lower in the conventional plan, because of the low-dose spread with VMAT (Fig. 3) . Also, the integral dose was invariably higher in the VMAT plans. Figure 1 Same coverage using both 3D-CRT (a) and VMAT (b) in a female patient with HL stage IIA.
VMAT versus 3D-CRT in Hodgkin's Lymphoma
For the four female patients included in this cohort; the V5, 10, 15 to the breasts were compared in both techniques with a higher dose for VMAT, particularly for patients in whom the disease involved the hilar and/or subcarinal region (Fig. 3) . Hilar involvement and bulky disease at the mid-and lower levels of mediastinum were however associated with unacceptable high doses to the lungs with 3D-CRT plans. For patients with non-bulky superior anterior mediastinal disease, the lowdose volume for lungs and both breasts was much lower for the conventional plan as compared to VMAT (Fig. 3) . In the four cases who presented with upper cervical disease, there was a better sparing of the parotid and thyroid with the VMAT as compared with 3D-CRT. The two patients with post-chemotherapy residual active disease, the total RT dose was escalated to 36 Gy, and it showed that the 3DCRT was associated with much higher V20 and mean dose to the lungs and heart when compared to VMAT.
Discussion
Radiation therapy is an integral component of combined modality treatment (CMT) in HL. The RT delivery has evolved over time, in an effort to reduce acute and long-term toxicities while maintaining the excellent cure rate. Most of HL cases can be managed with 3-DCRT using conventional 3D-CRT (AP/PA) techniques. This is particularly true in pediatric and adolescent cases where the prescribed RT dose is in the low range of 20-25 Gy. In adult HL however, RT standard doses range between 30 and 36 Gy, except for a small subset of patients with early-stage favorable HL where a lower dose of 20 Gy is used [1, 7] .
The conventional dose constraints used in treatment planning for most solid tumors do not appear to apply for lymphomas, since the relatively low RT doses needed in HL will result in most treatment plans being within the acceptable limits. However these may not constitute the optimal plan in terms of keeping RT dose to the normal structures to a minimum, in order to minimize the long-term toxicity. The RT field size was reduced over the last decades from extended field (EFRT) to involved-field (IFRT), and involved-nodal radiation (INRT), in an attempt to decrease the potential RTrelated toxicities. Based on clinical trials there is a general agreement to replace EFRT with IFRT in the modern era of CMT without compromising the outcome [8] [9] [10] . Recently, the International Lymphoma Radiation Oncology Group (ILROG) has developed guidelines for involved-field site (ISRT), since INRT may not be applicable in most clinical scenarios [4] . Nevertheless, there is still a wide variability between the different centers as to the extent of RT field applied in the current clinical practice (INRT, IFRT, or ISRT). Moreover, there is no agreement on the interpretation and implementation of ISRT, not only among different centers, but also among the most expert radiation oncologists, as has been shown in a recent ILROG study [11] . The choice of RT delivery technique depends on a number of factors: PTV coverage, dose to OARs, tumor volume, shape and location in relation to the individual anatomy, as well as patient gender and age (children, young females with mediastinal and axillary disease). Different clinical scenarios dictate the dose-priorities with respect to the OARs (co-existing morbid conditions: lung disease, bleomycin toxicity, heart disease). Finally, the choice of RT treatment technique largely depends on the treating radiation oncologist's expertise and the center's experience. A recent ILROG study showed that for the same set of case clinical scenarios, the treatment technique and planning methods widely varied across the ILROG centers, techniques being chosen according to the center's best practice [12] . These variations must be undoubtedly even greater among centers across the world.
In mediastinal disease close to the heart, the prescribed RT doses may not be achievable with 3D-CRT without potential significant lung and heart toxicity. This is particularly true in cases presenting with bulky mediastinal disease and chest wall or pericardial invasion. In these clinical situations, the conventional 3D-CRT plan cannot deliver the required dose to the PTV while meeting the OAR constraints because of the target anatomy overlapping with OARs. The use of more complex techniques such as optimized VMAT or IMRT allows dose ''tailoring" and offers better sparing of the critical structures. The trade-off with VMAT is that a larger volume of normal tissues being exposed to low-dose RT [2, 12, 13] . This increased low dose RT volume raises a major concern for a potential increased risk of developing second malignant tumor (SMT), especially breast cancer (BC) and thyroid cancer in female survivors [14] [15] [16] [17] . In a recent study, optimized VMAT using non co-planar arcs reduced the heart disease risk, as compared to 3D-CRT, with comparable estimated risks of thyroid and breast cancer, but with an increase in lung cancer induction probability [13] . The odds ratio for BC increases linearly with RT dose and decreases with the use of smaller RT volumes [13] ; hence the importance of reducing RT dose and volume in mediastinal irradiation, a finding which was proven in one important study, where exclusion of axillae from supradiaphragmatic RT fields was associated with a substantial reduction of Breast Cancer risk among females previously reported with mantle fields [15] .
In the current study, VMAT reduced the mean dose to heart and lungs, V30 heart and V20 lungs , in all the resulting plans. It was however associated with an increased volume of the normal tissues receiving low-dose radiation, due to delivery of highly conformal treatment through a rotational geometry of 1 or 2 arcs or hemi-arcs, and to the increased monitor units required for treatment delivery. Our data are comparable to the dose estimate comparison for ten patients with supra-diaphragmatic HL, planned using (3D CRT and VMAT, INRT/ISRT) in five ILROG centers having vast experience in the treatment of lymphomas [11] . Also, the increase in V5 and low-dose normal tissues with VMAT in the current study was comparable to other reports from similar studies [12, 13, [18] [19] [20] .
Deep inspiration breath-hold (DBH) gadget is not available at our center. Several studies have shown that DBH coupled with VMAT, IMRT or 3D-CRT is associated with better sparing of the heart and lungs than if the same techniques were used alone [18] .
In young female patients with disease limited to superior anterior mediastinum, 3D-CRT plans could result in better breast sparing as compared to VMAT. VMAT would give better sparing of breast and lung when the disease extends to midor lower mediastinum with hilar involvement. A ''butterfly" IMRT technique for mediastinal disease in young females was developed in MD Anderson Cancer Center (MDACC) [19] . This technique employs a special beam arrangement, daily breath hold, and CT-on-rails verification to achieve adequate target coverage, while reducing the high-and low-dose radiation exposure of the breasts and other critical organs. This technique is only applicable to disease confined to the mediastinum without any axillary involvement. Though the dose to the breasts is lower, the V5 lungs value for remains higher for the ''butterfly" as compared to 3DCRT AP/PA. VMAT has the advantage of a shorter treatment time and faster treatment delivery than IMRT. VMAT is also applicable in cases with sub-pectoral and axillary involvement. Another new alternative is proton therapy, though the role of proton has not yet been defined in HL, and it is not widely used because of the treatment cost, complexity, and availability.
Conclusions
This study shows that VMAT is a valuable technique for treatment of large mediastinal HL. It allows maximal lung and heart sparing when compared to 3D-CRT in select Hodgkin lymphoma patients treated with ISRT. In addition, it allows dose escalation when needed, with minimal increased dose to OARs. The main concern when using VMAT is the spreading of low radiation dose to the normal tissue and hence an increased integral dose. This raises concerns of possible increased risk of Second malignancy, particularly breast cancer when children and young female adolescent patients are treated. Long term data with regular follow up for treatmentinduced late toxicity is necessary before final conclusions can be made. ILROG guideline implementation and defining criteria for treatment plan evaluation for various clinical scenarios will refine radiation treatment, and will hopefully improve clinical outcomes for patients.
